Karyopharm Therapeutics Inc.
Karyopharm Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel first-in-class drugs targeting nuclear transport for the treatment of cancer and other major diseases. Karyopharm's lead candidate, is in ongoing clinical trials in multiple myeloma, lymphoma, and solid tumors; the company is currently preparing for its first potential U.S. commercial launch in 2019.